中文名：ZM 447439
英文名：ZM 447439
英文别名：N-(4-(6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-ylamino)phenyl)benzamide
纯度：10mM in DMSO
货号：Z408256
包装：1ml
Cas号：331771-20-1
存储温度：-80℃储存
产品介绍：
Information
ZM 447439 is a selective and ATP-competitive inhibitor forAurora AandAurora BwithIC50of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
In vitro
In vitro, ZM-447439 selectively inhibits recombinant human Aurora A and B with IC50 values of 110 and 130 nM, respectively, while other protein kinases of diverse structural types including the mitotic kinases CDK1 and PLK1 are inhibited with IC50 values >10 μM. Aurora kinase inhibitor, ZM-447439 time- and dose-dependently inhibits the growth of all three cell lines with IC50 values of 3 μM (BON), 0.9 μM (QGP-1) and 3 μM (MIP-101) after 72 hours of continuous exposure. In addition, ZM-447439 potently induces cell apoptosis by promoting DNA fragmentation and caspase 3 and 7 activation, and arrests GEP-NET cells in the G0 /G1and G2/M phase of the cell cycle. In mouse embryo, inhibition of Aurora kinase activity by ZM-447439 results in abnormalities during mitosis by regulating the phosphorylation of histone H3 serine 10 (H3S10Ph) from G2 to metaphase with different perturbations in each embryonic cycle. A recent study shows that ZM-447439 exhibits growth inhibitory and proapoptotic effect on cervical cancer SiHa cells, and enhances the chemosensitivity to cisplatin.
In vivo
Cell Data
cell lines：
Concentrations：0-5 μM
Incubation Time：72 hours
Powder Purity:≥96%
查看阿拉丁官网此产品相关对应页面：https://www.aladdin-e.com/zh_cn/Z408256.html
关键字： N-(4-(6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-ylamino)phenyl)benzamide
阿拉丁（A股科创板上市企业，股票代码：688179） 是科研服务领域的领先供应商与制造商，拥有科学服务领域领导品牌：阿拉丁。核心业务涵盖高端化学与生化试剂、生命科学、小分子及化合物库及材料科学四大领域，并自主拥有“芯硅谷”实验耗材品牌，依托电商平台实现线上主导的销售模式 。产品广泛服务于985/211高校、科研院所及生物医药、化工材料等领域220余家A股上市公司。
国内以上海化工园区、奉贤基地为核心，建成超7.6万㎡现代化产业集群 ，拥有GMP车间满足高品质多元需求，并配备全国五大仓储中心。研发投入超3亿元，建有化学、生物两大研发中心，每年推出超10,000种新产品，截至2025年10月拥有178项知识产权 ，产品SCI引用超25.3万篇，稳居国内科研试剂文献TOP3 。
战略立足全球，已在美国、德国等多地设5个公司布局 ，连续获《国家级专精特新“小巨人”企业》 、《中国化学试剂十强企业》 、《最受用户欢迎试剂品牌》 等荣誉，秉承“推动发现，推进科学”的理念，助力科研创新。